UY38721A - INHIBIDORES DE MOLÉCULAS PEQUEÑAS DE QUINASA INDUCTORA DE NF-kB - Google Patents

INHIBIDORES DE MOLÉCULAS PEQUEÑAS DE QUINASA INDUCTORA DE NF-kB

Info

Publication number
UY38721A
UY38721A UY0001038721A UY38721A UY38721A UY 38721 A UY38721 A UY 38721A UY 0001038721 A UY0001038721 A UY 0001038721A UY 38721 A UY38721 A UY 38721A UY 38721 A UY38721 A UY 38721A
Authority
UY
Uruguay
Prior art keywords
inductive
small molecule
molecule inhibitors
kinase small
disorders
Prior art date
Application number
UY0001038721A
Other languages
English (en)
Inventor
J Krawczuk Paul
Kent Barbay J
Wenying Chai
Wendy Eccles
T Herrmann Aaron
M Jones William
J Pippel Daniel
R Rovira Alexander
D Kreutter Kevin
L Wolin Ronald
D Hack Michael
D Lebsack Alec
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of UY38721A publication Critical patent/UY38721A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se relaciona con agentes farmacéuticos útiles para terapia y/o profilaxis en un mamífero, y en particular a los inhibidores de quinasa inductora de NF-kB (NIK - también conocidos como MAP3K14) útiles para tratar enfermedades tales como el cáncer (en particular malignidades de células B que incluyen leucemias, linfomas y mieloma), trastornos inflamatorios, trastornos autoinmunes y trastornos metabólicos que incluyen obesidad y diabetes.
UY0001038721A 2019-05-31 2020-05-29 INHIBIDORES DE MOLÉCULAS PEQUEÑAS DE QUINASA INDUCTORA DE NF-kB UY38721A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962855144P 2019-05-31 2019-05-31
US201962907833P 2019-09-30 2019-09-30

Publications (1)

Publication Number Publication Date
UY38721A true UY38721A (es) 2020-11-30

Family

ID=71108552

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038721A UY38721A (es) 2019-05-31 2020-05-29 INHIBIDORES DE MOLÉCULAS PEQUEÑAS DE QUINASA INDUCTORA DE NF-kB

Country Status (22)

Country Link
US (3) US11254673B2 (es)
EP (1) EP3976597B1 (es)
JP (1) JP7547387B2 (es)
KR (1) KR20220027871A (es)
CN (1) CN114222737B (es)
AU (1) AU2020282005A1 (es)
BR (1) BR112021023796A2 (es)
CA (1) CA3143350A1 (es)
CL (1) CL2021003142A1 (es)
CO (1) CO2021017838A2 (es)
CR (1) CR20210587A (es)
DK (1) DK3976597T3 (es)
DO (1) DOP2021000244A (es)
EC (1) ECSP21093623A (es)
IL (1) IL288387A (es)
JO (1) JOP20210318A1 (es)
MA (1) MA56038A (es)
MX (1) MX2021014679A (es)
PE (1) PE20220768A1 (es)
SG (1) SG11202112994WA (es)
UY (1) UY38721A (es)
WO (1) WO2020239999A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020239999A1 (en) * 2019-05-31 2020-12-03 Janssen Pharmaceutica Nv SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE
MX2021014441A (es) 2019-05-31 2022-01-06 Ikena Oncology Inc Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
WO2023217906A1 (en) * 2022-05-11 2023-11-16 Janssen Pharmaceutica Nv Pyrrolidinone derivatives as inhibitors of nf kappa b inducing kinase
WO2023217879A1 (en) * 2022-05-11 2023-11-16 Janssen Pharmaceutica Nv Pyrrolidione derivatives as inhibitors of nf kappa b inducing kinase
US20240279230A1 (en) 2022-12-22 2024-08-22 Boehringer Ingelheim International Gmbh Crystalline forms of a her2 inhibitor

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
US7132428B2 (en) 2003-07-03 2006-11-07 Aventis Pharmaceuticals Inc. Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders
TW200605886A (en) * 2004-08-03 2006-02-16 Wyeth Corp Indazoles useful in treating cardiovascular diseases
KR101227228B1 (ko) 2004-11-12 2013-01-28 스태츠 칩팩, 엘티디. 와이어 본드 배선
AU2009263037B2 (en) 2008-06-26 2011-10-06 Amgen Inc. Alkynyl alcohols as kinase inhibitors
US20110183975A1 (en) 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
AR085908A1 (es) 2011-03-16 2013-11-06 Hoffmann La Roche DERIVADOS DE 3-BUTIN-2-OL Y DE CARBONITRILO CON ACTIVIDAD INHIBIDORA DE LA QUINASA INDUCTORA DE NF-kB (NIK)
MX2014009624A (es) 2012-02-17 2015-03-19 Hoffmann La Roche Compuestos triciclicos y metodos para el uso de los mismos.
US8859553B2 (en) 2012-07-30 2014-10-14 Astar Biotech Llc Protein kinase inhibitors
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
US20160096850A9 (en) * 2013-08-22 2016-04-07 Genentech, Inc. Alkynyl alcohols and methods of use
JP2016531127A (ja) 2013-08-22 2016-10-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ アルキニルアルコール及び使用方法
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
CA2960336C (en) 2014-10-23 2023-03-07 Janssen Pharmaceutica Nv Compounds as nik inhibitors
ES2715104T3 (es) 2014-10-23 2019-05-31 Janssen Pharmaceutica Nv Nuevos derivados de pirazolopirimidina como inhibidores de nik
ES2704738T3 (es) 2014-10-23 2019-03-19 Janssen Pharmaceutica Nv Nuevos derivados de tienopirimidina en calidad de inhibidores de nik
CN107074818B (zh) 2014-10-23 2020-04-17 詹森药业有限公司 作为nik抑制剂的吡唑衍生物
WO2016135163A1 (en) 2015-02-25 2016-09-01 F. Hoffmann-La Roche Ag Alkynyl alcohols and methods of use
LT3405196T (lt) 2016-01-22 2020-02-25 Janssen Pharmaceutica Nv Naujieji pakeistieji cianoindolino dariniai kaip nik inhibitoriai
KR20180098679A (ko) 2016-01-22 2018-09-04 잔센파마슈티카엔.브이. Nik 억제제로서의 신규 6원 헤테로방향족 치환된 시아노인돌린 유도체
WO2018002219A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Cyanoindoline derivatives as nik inhibitors
ES2805976T3 (es) 2016-06-30 2021-02-16 Janssen Pharmaceutica Nv Derivados heteroaromáticos en calidad de inhibidores de NIK
JP7138093B2 (ja) * 2016-08-24 2022-09-15 エフ．ホフマン－ラ ロシュ アーゲー ２－アザビシクロ［３．１．０］ヘキサン－３－オン誘導体及び使用方法
WO2018037059A1 (en) 2016-08-24 2018-03-01 F. Hoffmann-La Roche Ag 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use
EP3649127B1 (en) 2017-07-06 2021-09-08 Janssen Pharmaceutica NV Substituted azaindoline derivatives as nik inhibitors
CN109810110B (zh) 2017-11-22 2023-01-24 中国科学院上海药物研究所 一种具有2-氨基嘧啶结构的化合物，其制备方法和用途
PE20230244A1 (es) 2019-05-31 2023-02-07 Sage Therapeutics Inc Esteroides neuroactivos y composiciones de estos
MX2021014441A (es) 2019-05-31 2022-01-06 Ikena Oncology Inc Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
CA3142351A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2020239999A1 (en) * 2019-05-31 2020-12-03 Janssen Pharmaceutica Nv SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE
MX2021014115A (es) 2019-05-31 2021-12-10 Chiesi Farm Spa Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3).
KR20220075382A (ko) 2019-09-30 2022-06-08 인사이트 코포레이션 면역조절제로서의 피리도[3,2-d]피리미딘 화합물

Also Published As

Publication number Publication date
BR112021023796A2 (pt) 2022-02-08
PE20220768A1 (es) 2022-05-16
JOP20210318A1 (ar) 2023-01-30
MA56038A (fr) 2022-04-06
EP3976597A1 (en) 2022-04-06
EP3976597B1 (en) 2024-08-28
DK3976597T3 (da) 2024-09-09
MX2021014679A (es) 2022-04-06
US20230080834A1 (en) 2023-03-16
US20240199605A1 (en) 2024-06-20
SG11202112994WA (en) 2021-12-30
CA3143350A1 (en) 2020-12-03
CN114222737A (zh) 2022-03-22
IL288387A (en) 2022-01-01
DOP2021000244A (es) 2022-04-18
CO2021017838A2 (es) 2022-01-17
ECSP21093623A (es) 2022-01-31
KR20220027871A (ko) 2022-03-08
US11254673B2 (en) 2022-02-22
CN114222737B (zh) 2024-07-26
CL2021003142A1 (es) 2022-08-19
US11827634B2 (en) 2023-11-28
JP2022534302A (ja) 2022-07-28
JP7547387B2 (ja) 2024-09-09
US20210300918A1 (en) 2021-09-30
WO2020239999A1 (en) 2020-12-03
CR20210587A (es) 2022-02-11
AU2020282005A1 (en) 2021-12-23
TW202110842A (zh) 2021-03-16

Similar Documents

Publication Publication Date Title
UY38721A (es) INHIBIDORES DE MOLÉCULAS PEQUEÑAS DE QUINASA INDUCTORA DE NF-kB
CO2020002588A2 (es) Composiciones que comprenden un inhibidor de shp2 y metodos para tratar el cáncer
CO2020011908A2 (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a/a2b
NI201900019A (es) Inhibidores de procesos metabólicos celulares
GT201400089A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CO2018013293A2 (es) Derivados de pirazolopirimidina como inhibidor de quinasa
BR112018077136A2 (pt) composto, e, métodos para tratar um distúrbio associado com proliferação celular anormal e para reduzir o efeito de quimioterapia em células saudáveis.
CL2018000803A1 (es) Composiciones y métodos para inhibir la expresión génica de lpa.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2020002840A1 (es) Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos
CR20190394A (es) Compuestos de inhibidores de autotaxina
CL2016003301A1 (es) Compuestos derivados del ácido amino-(piridin-4-carboxílico) sustituidos, inhibidores de la histona desmetilasa; composición farmacéutica, que los comprende, útiles en el tratamiento del cáncer, tales como el cáncer de próstata, mama, vejiga, pulmón y/o melanoma.
GT201300215A (es) Inhibidores de glucosilceramida sintasa
BR112015021371A2 (pt) uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares
BR112017008045A2 (pt) compostos como inibidores de nik
CL2016001409A1 (es) Inhibidores de quinasa relacionada con la tropomiosina (trk).
ECSP20024210A (es) Uso de inhibidores de p38 para reducir la expresión de dux4
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
ECSP20061378A (es) COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-gamma
BR112017007704A2 (pt) derivados de pirazolopirimidina como inibidores de nik
CO2019000753A2 (es) Métodos para tratar el cáncer de próstata
CR20150496A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
UY36416A (es) 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de la mieloperoxidasa
BR112022007376A2 (pt) Terapias de combinação com venetoclax e inibidores de tim-3